Fate Therapeutics (FATE) Operating Income (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Operating Income came in at -$33.0 million in Q1 2026, up 20.06% YoY from -$27.5 million in Q1 2025, and up 4.96% on a QoQ basis from -$34.7 million in Q4 2025.
Fate Therapeutics (FATE) Operating Income (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Operating Income data on file, last reported at -$33.0 million in Q1 2026.
- Quarterly Operating Income rose 20.06% year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$139.4 million (up 30.46% YoY) and the FY2025 annual result came in at -$147.7 million, up 29.76% from the prior year.
- Operating Income improved to -$33.0 million in Q1 2026, from -$34.7 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$28.6 million in Q1 2023 to a low of -$86.4 million in Q3 2022.
- A 5-year average of -$52.3 million and a median of -$51.1 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income soared 61.6% — and 2024, when it tumbled 78.61%.
- Tracing FATE's Operating Income over 5 years: stood at -$64.4 million in 2022, then rose by 25.37% to -$48.1 million in 2023, then fell by 28.44% to -$61.7 million in 2024, then jumped by 43.77% to -$34.7 million in 2025, then rose by 4.96% to -$33.0 million in 2026.
- The last three Operating Income figures came in at -$33.0 million (Q1 2026), -$34.7 million (Q4 2025), and -$34.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -33.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.00 Mn |
| Dec 31, 2025 | -34.72 Mn |
| Sep 30, 2025 | -34.74 Mn |
| Jun 30, 2025 | -36.97 Mn |
| Mar 31, 2025 | -41.28 Mn |
| Dec 31, 2024 | -61.75 Mn |
| Sep 30, 2024 | -52.38 Mn |
| Jun 30, 2024 | -45.08 Mn |
| Mar 31, 2024 | -51.07 Mn |
| Dec 31, 2023 | -48.08 Mn |
| Sep 30, 2023 | -51.28 Mn |
| Jun 30, 2023 | -62.57 Mn |
| Mar 31, 2023 | -28.59 Mn |
| Dec 31, 2022 | -64.42 Mn |
| Sep 30, 2022 | -86.39 Mn |
| Jun 30, 2022 | -83.11 Mn |
| Mar 31, 2022 | -74.47 Mn |
| Dec 31, 2021 | -69.38 Mn |
| Sep 30, 2021 | -54.62 Mn |
| Jun 30, 2021 | -46.78 Mn |